Middle East Pharmaceutical Industries Co. (4016.SR)
SAR 120.2
(-0.5%)
SAR 120.2
(-0.5%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 78.24 Million SAR | 11.25% |
| 2022 | 70.33 Million SAR | -8.08% |
| 2021 | 76.51 Million SAR | -5.6% |
| 2020 | 81.05 Million SAR | 34.32% |
| 2019 | 60.34 Million SAR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 24.52 Million SAR | 98.89% |
| 2024 Q1 | 12.33 Million SAR | -54.57% |
| 2023 Q4 | 27.14 Million SAR | 0.0% |
| 2023 Q3 | 27.14 Million SAR | 30.01% |
| 2023 FY | 78.68 Million SAR | 11.86% |
| 2023 Q2 | 20.87 Million SAR | 826.62% |
| 2023 Q1 | 2.25 Million SAR | -90.37% |
| 2022 Q1 | 11.32 Million SAR | 0.0% |
| 2022 FY | 70.33 Million SAR | -8.08% |
| 2022 Q4 | 23.38 Million SAR | 0.0% |
| 2022 Q2 | 23.55 Million SAR | 108.06% |
| 2022 Q3 | 23.38 Million SAR | -0.72% |
| 2021 FY | 76.51 Million SAR | -5.6% |
| 2020 FY | 81.05 Million SAR | 34.32% |
| 2019 FY | 60.34 Million SAR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Al-Dawaa Medical Services Company | 466.68 Million SAR | 83.233% |
| Nahdi Medical Company | 960.95 Million SAR | 91.857% |
| Al-Razi Medical Co. | 1.81 Million SAR | -4217.413% |
| Almujtama Alraida Medical Co. | 13.94 Million SAR | -460.996% |